| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | -29.3MM | +7% |
| Operating Expenses | 29.3MM | +7% |
| Net Income | -24.6MM | +9% |
| R&D | 20.5MM | +12% |
| G&A | 8.8MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
A look at three stocks where technical analysis can help and the TAZR service.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs. And they offer the potential for creating fabulous wealth for investors willing to get in early enough. Yet, biotechs can also plunge to new depths when their drug trials go awry. It’s definitely not a sector to invest in for the faint of heart. Finding the right horse to back is a key consideration. Below a
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries. The pandemic amplified These health-related issues, leading to sky-high demand for the companies’ weight-loss treatments. Now, some concerns around potential side effects and the ability to wean off of these drugs once a target weight has been hit are starting to ruminate in the ma